Table 3.

Adverse events.

	Amantadine (N = 23)	Placebo (N = 29)
Cardiac disorders	3 (13%)	2 (6.9%)
Gastrointestinal disorders	0 (0%)	1 (3.4%)
General disorders and administration site conditions	4 (17.4%)	1 (3.4%)
Infections and infestations	1 (4.3%)	3 (10.3%)
Injury, poisoning and procedural complication	0 (0%)	1 (3.4%)
Nervous system disorders	0 (0%)	1 (3.4%)
Psychiatric disorders	1 (4.3%)	0 (0%)
Renal and urinary disorders	0 (0%)	1 (3.4%)
Respiratory, thoracic and mediastinal disorders	11 (47.8%)	14 (48.3%)
Vascular disorders	2 (8.7%)	5 (17.2%)
No data	1 (4.3%)	0 (0%)
Major adverse cardiovascular events	1 (5%)	2 (6.9%)
Death	10 (43.5%)	7 (24.1%)
Association with treatment
Unlikely	20 (87%)	24 (82.8%)
Unknown	1 (4.3%)	3 (10.3%)
Likely	2 (8.7%)	2 (6.9%)
SAEs likely associated with treatment
Cardiac disorders	1 (50%)	1 (50%)
Gastrointestinal disorders	0 (0%)	1 (50%)
Psychiatric disorders	1 (50%)	0 (0%)
Major adverse cardiovascular events	0 (0%)	1 (50%)